A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma
|ClinicalTrials.gov Identifier: NCT00668499|
Recruitment Status : Withdrawn (Sponsor withdrew support)
First Posted : April 29, 2008
Last Update Posted : May 21, 2014
This will be a single institution non-randomized phase I/II trial for patients with malignant mesothelioma stage II and above, who have not received prior chemotherapy for their disease.
The purpose of this phase is to select a dose of VEGF-AS (antiangiogenesis drug)to be given with standard doses of pemetrexed followed by cisplatin on day 1 of a 21-day cycle.
|Condition or disease||Intervention/treatment||Phase|
|Mesothelioma||Drug: VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin||Phase 1 Phase 2|
The Study Objectives in Phase I are:
To determine the safety of the combination of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin™) plus Pemetrexed and Cisplatin in subjects with advanced Malignant Mesothelioma,.via a dose escalation protocol. To determine the Maximum Tolerated Dose (MTD) and Dose Limiting Toxicity (DLT) of VEGF-AS plus Premetrexed and Cisplatin. To determine the time to disease progression To determine the objective response rate of the combination of VEGF-AS plus Pemetrexed and Cisplatin for the treatment of advanced malignant mesothelioma
The study Objectives in Phase II are:
To further characterize the toxicity experienced by patients with malignant mesothelioma treated with VEGF-AS plus Cisplatin and Pemetrexed.
To determine median and overall survival.
The Laboratory objectives are:
To measure plasma VEGF levels before, during, and after therapy as a correlate of outcome. To determine the pharmacokinetic profile of VEGF-AS plus Pemetrexed and Cisplatin.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin) in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma|
|Study Start Date :||April 2008|
|Estimated Primary Completion Date :||April 2011|
|Estimated Study Completion Date :||April 2011|
Drug: VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin
- The primary endpoint of the phase II trial will be time to progression [ Time Frame: Tumor measurements every 6 weeks ]
- Secondary endpoints are objective response rate and overall survival [ Time Frame: Every 6 weeks evaluations ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00668499
|United States, California|
|USC/Norris Comprehensive Cancer Center|
|Los Angeles, California, United States, 90033|
|Principal Investigator:||Barbara Gitlitz, MD||University of Southern California|